CN113244209A - 柠檬酸铁在治疗慢性肾脏疾病患者中的应用 - Google Patents

柠檬酸铁在治疗慢性肾脏疾病患者中的应用 Download PDF

Info

Publication number
CN113244209A
CN113244209A CN202110644193.4A CN202110644193A CN113244209A CN 113244209 A CN113244209 A CN 113244209A CN 202110644193 A CN202110644193 A CN 202110644193A CN 113244209 A CN113244209 A CN 113244209A
Authority
CN
China
Prior art keywords
ferric citrate
iron
patient
increase
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110644193.4A
Other languages
English (en)
Chinese (zh)
Inventor
恩里克·普拉多苏
罗恩·本图尔
詹姆斯·F·奥利维耶罗三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of CN113244209A publication Critical patent/CN113244209A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110644193.4A 2012-06-21 2013-06-21 柠檬酸铁在治疗慢性肾脏疾病患者中的应用 Pending CN113244209A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US61/662,565 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US61/757,229 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
US61/801,050 2013-03-15
US61/800,618 2013-03-15
CN201380044271.0A CN104884055A (zh) 2012-06-21 2013-06-21 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380044271.0A Division CN104884055A (zh) 2012-06-21 2013-06-21 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Publications (1)

Publication Number Publication Date
CN113244209A true CN113244209A (zh) 2021-08-13

Family

ID=49769729

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110644193.4A Pending CN113244209A (zh) 2012-06-21 2013-06-21 柠檬酸铁在治疗慢性肾脏疾病患者中的应用
CN201380044271.0A Pending CN104884055A (zh) 2012-06-21 2013-06-21 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380044271.0A Pending CN104884055A (zh) 2012-06-21 2013-06-21 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Country Status (19)

Country Link
US (3) US20130345303A1 (https=)
EP (3) EP3730136B1 (https=)
JP (4) JP2015535209A (https=)
KR (2) KR20200103855A (https=)
CN (2) CN113244209A (https=)
AU (2) AU2013278000A1 (https=)
BR (1) BR112014032049A2 (https=)
CA (1) CA2876982A1 (https=)
DK (1) DK3730136T3 (https=)
EA (1) EA201590062A1 (https=)
ES (2) ES2796254T3 (https=)
FR (1) FR25C1043I1 (https=)
HK (1) HK1214503A1 (https=)
IL (1) IL236356A0 (https=)
MX (1) MX2014015615A (https=)
NO (1) NO2025048I1 (https=)
PL (1) PL3730136T3 (https=)
SG (2) SG11201408521WA (https=)
WO (1) WO2013192565A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115024495A (zh) * 2022-06-27 2022-09-09 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
HK1223031A1 (zh) * 2013-11-04 2017-07-21 凯克斯生物制药公司 用於降低慢性肾病患者的心力衰竭的枸橼酸铁
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
US20180071243A1 (en) * 2015-03-04 2018-03-15 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US20210085711A1 (en) 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
JP2022505697A (ja) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー／エス カルボキシマルトース第二鉄による鉄欠乏症の治療
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
CN1751056A (zh) * 2003-02-19 2006-03-22 环亚有限公司 铁有机化合物、其应用及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922461A4 (en) * 1996-07-19 2002-07-17 Nikken Chemicals Co Ltd MEDICINE AGAINST HYPERPHOSPHATANEMIA
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP1973549B1 (en) * 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1751056A (zh) * 2003-02-19 2006-03-22 环亚有限公司 铁有机化合物、其应用及其制备方法
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115024495A (zh) * 2022-06-27 2022-09-09 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用

Also Published As

Publication number Publication date
ES2796254T3 (es) 2020-11-26
EP3730136B1 (en) 2023-12-27
EP4335436A3 (en) 2024-05-15
US20140234416A1 (en) 2014-08-21
HK1214503A1 (zh) 2016-07-29
JP2015535209A (ja) 2015-12-10
EP2863906B1 (en) 2020-03-18
EP4335436A2 (en) 2024-03-13
IL236356A0 (en) 2015-02-26
WO2013192565A2 (en) 2013-12-27
AU2018203205B2 (en) 2020-03-12
KR20200103855A (ko) 2020-09-02
MX2014015615A (es) 2015-03-20
US20150079168A1 (en) 2015-03-19
JP2020100638A (ja) 2020-07-02
HK1210013A1 (en) 2016-04-15
SG10201805177PA (en) 2018-07-30
BR112014032049A2 (pt) 2017-07-25
JP2022070945A (ja) 2022-05-13
AU2013278000A1 (en) 2015-01-22
CA2876982A1 (en) 2013-12-27
US20130345303A1 (en) 2013-12-26
PL3730136T3 (pl) 2024-03-25
DK3730136T3 (da) 2024-01-22
KR102150135B1 (ko) 2020-08-31
EP2863906A2 (en) 2015-04-29
NO2025048I1 (no) 2025-11-06
ES2970050T3 (es) 2024-05-24
AU2018203205A1 (en) 2018-05-31
EA201590062A1 (ru) 2016-02-29
EP3730136A1 (en) 2020-10-28
WO2013192565A3 (en) 2015-10-15
JP2018138562A (ja) 2018-09-06
CN104884055A (zh) 2015-09-02
FR25C1043I1 (fr) 2026-01-02
KR20150036131A (ko) 2015-04-07
SG11201408521WA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
TWI744215B (zh) 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途
CN107115414A (zh) 用于预防及治疗第2型糖尿病的营养品组合
CN107530310A (zh) 柠檬酸铁在治疗缺铁性贫血中的用途
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210813

WD01 Invention patent application deemed withdrawn after publication